Literature DB >> 31231031

Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues.

Dobeen Hwang1, Napon Nilchan2, Alex R Nanna3, Xiaohai Li4, Michael D Cameron4, William R Roush2, HaJeung Park5, Christoph Rader6.   

Abstract

Homogeneous antibody-drug conjugates (ADCs) that use a highly reactive buried lysine (Lys) residue embedded in a dual variable domain (DVD)-IgG1 format can be assembled with high precision and efficiency under mild conditions. Here we show that replacing the Lys with an arginine (Arg) residue affords an orthogonal ADC assembly that is site-selective and stable. X-ray crystallography confirmed the location of the reactive Arg residue at the bottom of a deep pocket. As the Lys-to-Arg mutation is confined to a single residue in the heavy chain of the DVD-IgG1, heterodimeric assemblies that combine a buried Lys in one arm, a buried Arg in the other arm, and identical light chains, are readily assembled. Furthermore, the orthogonal conjugation chemistry enables the loading of heterodimeric DVD-IgG1s with two different cargos in a one-pot reaction and thus affords a convenient platform for dual-warhead ADCs and other multifaceted antibody conjugates.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Site-specific antibody conjugation; antibody-drug conjugates; cancer therapy; catalytic antibodies; dual variable domain; orthogonal antibody conjugation; phenylglyoxal; β-lactam

Year:  2019        PMID: 31231031      PMCID: PMC6754284          DOI: 10.1016/j.chembiol.2019.05.010

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  47 in total

1.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

2.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

3.  Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task.

Authors:  A Karlstrom; G Zhong; C Rader; N A Larsen; A Heine; R Fuller; B List; F Tanaka; I A Wilson; C F Barbas; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

4.  A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.

Authors:  Christoph Rader; James M Turner; Andreas Heine; Doron Shabat; Subhash C Sinha; Ian A Wilson; Richard A Lerner; Carlos F Barbas
Journal:  J Mol Biol       Date:  2003-09-26       Impact factor: 5.469

5.  Direct observation of an enamine intermediate in amine catalysis.

Authors:  Xueyong Zhu; Fujie Tanaka; Richard A Lerner; Carlos F Barbas; Ian A Wilson
Journal:  J Am Chem Soc       Date:  2009-12-30       Impact factor: 15.419

6.  Bio-orthogonal phosphatidylserine conjugates for delivery and imaging applications.

Authors:  Andrew J Lampkins; Edward J O'Neil; Bradley D Smith
Journal:  J Org Chem       Date:  2008-07-11       Impact factor: 4.354

Review 7.  Potent antibody drug conjugates for cancer therapy.

Authors:  Peter D Senter
Journal:  Curr Opin Chem Biol       Date:  2009-05-04       Impact factor: 8.822

8.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

Authors:  Chengbin Wu; Hua Ying; Christine Grinnell; Shaughn Bryant; Renee Miller; Anca Clabbers; Sahana Bose; Donna McCarthy; Rong-Rong Zhu; Ling Santora; Rachel Davis-Taber; Yune Kunes; Emma Fung; Annette Schwartz; Paul Sakorafas; Jijie Gu; Edit Tarcsa; Anwar Murtaza; Tariq Ghayur
Journal:  Nat Biotechnol       Date:  2007-10-14       Impact factor: 54.908

9.  Solving structures of protein complexes by molecular replacement with Phaser.

Authors:  Airlie J McCoy
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-12-13

10.  Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.

Authors:  J Kurebayashi; T Otsuki; C K Tang; M Kurosumi; S Yamamoto; K Tanaka; M Mochizuki; H Nakamura; H Sonoo
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  7 in total

1.  Reactive Oxygen Species (ROS) Activated Liposomal Cell Delivery using a Boronate-Caged Guanidine Lipid.

Authors:  Jinchao Lou; Megan L Qualls; Macy M Hudson; Dillon P McBee; Joshua A Baccile; Michael D Best
Journal:  Chemistry       Date:  2022-06-27       Impact factor: 5.020

2.  Characterization of TnmH as an O-Methyltransferase Revealing Insights into Tiancimycin Biosynthesis and Enabling a Biocatalytic Strategy To Prepare Antibody-Tiancimycin Conjugates.

Authors:  Ajeeth Adhikari; Christiana N Teijaro; Xiaohui Yan; Chin-Yuan Chang; Chun Gui; Yu-Chen Liu; Ivana Crnovcic; Dong Yang; Thibault Annaval; Christoph Rader; Ben Shen
Journal:  J Med Chem       Date:  2020-07-24       Impact factor: 7.446

3.  Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates.

Authors:  Dobeen Hwang; Kohei Tsuji; HaJeung Park; Terrence R Burke; Christoph Rader
Journal:  Bioconjug Chem       Date:  2019-11-01       Impact factor: 4.774

4.  An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation.

Authors:  Napon Nilchan; James M Alburger; William R Roush; Christoph Rader
Journal:  Biochemistry       Date:  2021-03-23       Impact factor: 3.162

5.  Site-Specific Antibody-Drug Conjugates in Triple Variable Domain Fab Format.

Authors:  Dobeen Hwang; Christoph Rader
Journal:  Biomolecules       Date:  2020-05-14

Review 6.  Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.

Authors:  Xinling Zhang; Andrew C Huang; Fahai Chen; Hu Chen; Lele Li; Nana Kong; Wenting Luo; Jianmin Fang
Journal:  Antib Ther       Date:  2022-01-27

7.  A new immunochemical strategy for triple-negative breast cancer therapy.

Authors:  Chih-Wei Lin; Tianqing Zheng; Geramie Grande; Alex R Nanna; Christoph Rader; Richard A Lerner
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.